Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 51: 808-809, 2005; 10.1373/clinchem.2005.048553
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Millington, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Millington, D. S.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Pediatric Clinical Chemistry
Right arrow Proteomics and Protein Markers
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2005;51:808-809.)
© 2005 American Association for Clinical Chemistry, Inc.


Editorials

Newborn Screening for Lysosomal Storage Disorders

David S. Millington

Duke University Medical Center, Biochemical Genetics Laboratory, 99 Alexander Drive, PO Box 14991, Research Triangle Park, NC 27709, Fax 919-549-0709, E-mail dmilli@duke.edu

The first 20% of the full text of this article appears below.

The concept of screening newborns for inherited metabolic disorders was the brainchild of Robert Guthrie, an upstate New York microbiologist with a passion to prevent the devastating and irreversible neurologic damage sustained by victims of untreated phenylketonuria (PKU). The solution he developed was a simple and inexpensive bacterial inhibition assay for phenylalanine in blood (1). He also invented a unique method of specimen collection, in which peripheral blood was collected from a newborn’s pricked heel onto a special cotton fiber filter-paper known as a "PKU card" or "Guthrie card". After the blood had dried, the specimen was mailed to a laboratory that would identify any child at risk for PKU from a concentration of phenylalanine above an age-matched control limit. Further diagnostic testing was then required to determine whether the disease was present. Treating affected children with a phenylalanine-depleted diet, started within the first month of life, was effective in preventing mental retardation. Unable to persuade the state of New York to conduct newborn screening with the test, Guthrie convinced Massachusetts that the cost of screening the entire population of newborns and treating affected children with the special diet was less than the cost to society of untreated PKU cases. Thus, in 1963 began state-mandated newborn screening for PKU (2). The test was gradually adopted by other states and eventually by countries all over the world.

The success of PKU screening in dried blood spots (DBS), which identifies ~200 new cases annually in the United States alone, prompted the addition of tests for other disorders that fit the PKU paradigm. By the mid-1990s, . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Chem.Home page
D. S. Millington
Rapid and Effective Screening for Lysosomal Storage Disease: How Close Are We?
Clin. Chem., October 1, 2008; 54(10): 1592 - 1594.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.